What is Teewinot Life Sciences?
Teewinot Life Sciences operates at the intersection of biotechnology and pharmaceutical manufacturing, specializing in the ethical development of cannabinoid-based drugs. Through its subsidiary, Full Spectrum Laboratories, Ltd., the company utilizes patented biocatalytic processes to synthesize pure cannabinoids, effectively bypassing the limitations of traditional extraction methods. Headquartered in Tampa, Florida, the firm is uniquely positioned to disrupt the market by providing high-purity, pharmaceutical-grade ingredients that meet rigorous industry standards. Their business model centers on both direct drug development and the licensing of proprietary technology, establishing a dual-revenue stream that enhances their market resilience and long-term growth potential.
How much funding has Teewinot Life Sciences raised?
Teewinot Life Sciences has raised a total of $19.3M across 2 funding rounds:
Series A
$7M
Series B
$12.3M
Series A (2016): $7M with participation from Tuatara Capital
Series B (2017): $12.3M led by Tuatara Capital
Key Investors in Teewinot Life Sciences
Tuatara Capital
Tuatara Capital is a specialized investment firm dedicated to supporting innovative entrepreneurs in building successful companies within the cannabis ecosystem. They focus on forming foundational partnerships, providing strategic guidance and resources throughout the business lifecycle to foster growth-stage success.
What's next for Teewinot Life Sciences?
With the successful closure of this major strategic investment, Teewinot Life Sciences is poised to transition from a development-focused entity to a commercial-scale powerhouse. The company's roadmap includes the optimization of its synthetic biology platforms to increase yield and reduce production costs, which is essential for achieving widespread adoption in the clinical sector. Future growth will likely be driven by the expansion of its licensing agreements and the advancement of its internal drug pipeline through clinical trials. As the regulatory environment for cannabinoid-based medicine continues to evolve, Teewinot's commitment to scientific rigor and intellectual property protection will be critical in maintaining its competitive advantage and securing its role as a leader in the next generation of biopharmaceutical innovation.
See full Teewinot Life Sciences company page
